Capital ConstraintsCapital constraints are a main challenge, with potential pressure on the stock if the FDA requires another randomized Phase 2 trial.
Funding RequirementsCervomed Inc. will need to raise capital to conduct a Phase 3 program, with a modeled $25 million raise expected on the back of open-label extension data.
Market ConditionsA Phase 3 trial would require additional funding, and current volatile macro conditions present challenges for small/mid-cap biotech stocks like CRVO.